» Articles » PMID: 28288829

Serum Hepatitis B Core-related Antigen is More Accurate Than Hepatitis B Surface Antigen to Identify Inactive Carriers, Regardless of Hepatitis B Virus Genotype

Overview
Publisher Elsevier
Date 2017 Mar 15
PMID 28288829
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To investigate whether hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) levels are useful to identify inactive carriers among HBeAg-negative patients infected by different hepatitis B virus (HBV) genotypes.

Methods: In all, 202 consecutive HBeAg-negative patients with chronic hepatitis B, 135 inactive carriers and 67 with HBV activity, were prospectively followed for 1 year.

Results: In HBeAg-negative patients, HBsAg levels differed across the different genotypes (p <0.001). The highest levels were observed in genotypes F or H (4.2 ± 0.6 logIU/mL), followed by genotype E (3.4 ± 1.1 logIU/mL), genotype A (3.4 ± 0.8 logIU/mL), and the lowest in genotype D (2.7 ± 1.1 logIU/mL). Variations in HBsAg levels were similar in inactive carriers and patients with HBV activity. HBsAg <3 logIU/mL showed good performance for identifying genotype D inactive carriers: 76% of genotype D inactive carriers met this cut-off versus ≤31% for genotypes A, E, F or H. However, in patients with genotype A, HBsAg levels ≤3.7 logIU/mL better classified inactive carriers. The combination of a single measurement of HBcrAg ≤3 logU/mL plus HBV DNA ≤2000 IU/mL yielded a positive predictive value and diagnostic accuracy >85% in all HBV genotypes, except genotype H or F, with values of 62.5% and 72.7%, respectively, for the two parameters.

Conclusions: HBsAg levels varied across genotypes in HBeAg-negative patients. HBsAg levels <3 logIU/mL were only useful for identifying genotype D inactive carriers. A single HBcrAg measurement ≤3 logU/mL plus HBV DNA ≤2000 IU/mL was highly accurate for identifying inactive carriers, regardless of their HBV genotype.

Citing Articles

Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure.

Qiu Y, Tang Q, Liu X, Xue Y, Zeng Y, Hu P World J Hepatol. 2025; 17(1):98658.

PMID: 39871916 PMC: 11736480. DOI: 10.4254/wjh.v17.i1.98658.


Predictive Factors for HBsAg Loss in Chronic HBeAg-Negative Hepatitis B Virus Infection: Insights From a 5-Year French Cohort.

Causse X, Potier P, Valery A, Labadie H, Macaigne G, Cadranel J J Viral Hepat. 2024; 32(1):e14041.

PMID: 39673688 PMC: 11646079. DOI: 10.1111/jvh.14041.


Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment.

Sandmann L, Bremer B, Ohlendorf V, Jaroszewicz J, Wedemeyer H, Cornberg M Viruses. 2024; 16(2).

PMID: 38400031 PMC: 10891644. DOI: 10.3390/v16020255.


HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers.

Roade L, Riveiro-Barciela M, Pfefferkorn M, Sopena S, Palom A, Bes M JHEP Rep. 2023; 5(10):100842.

PMID: 37745192 PMC: 10514556. DOI: 10.1016/j.jhepr.2023.100842.


Hepatitis B Virus Genotype D: An Overview of Molecular Epidemiology, Evolutionary History, and Clinical Characteristics.

SantAnna T, Araujo N Microorganisms. 2023; 11(5).

PMID: 37317074 PMC: 10221421. DOI: 10.3390/microorganisms11051101.